title: Effect of ligands that increase cAMP on caerulein-induced zymogen activation in pancreatic acini.
abstract: The pathological activation of proteases within the pancreatic acinar cell is critical to initiating pancreatitis. Stimulation of acinar cells with supraphysiological concentrations of the CCK analog caerulein (CER) leads to protease activation and pancreatitis. Agents that sensitize the acinar cell to the effects of CCK might contribute to disease. The effects of physiological ligands that increase acinar cell cAMP [secretin, VIP, and pituitary adenylate cyclase activating peptide (PACAP)] on CER-induced responses were examined in isolated rat pancreatic acini. Each ligand sensitized the acinar cell to zymogen activation by physiological concentrations of CER (0.1 nM). VIP and PACAP but not secretin also enhanced activation by supraphysiological concentrations of CER (0.1 muM). A cell-permeable cAMP analog also sensitized the acinar cell to CER-induced activation. The cAMP antagonist Rp-8-Br-cAMP inhibited these sensitizing effects. These findings suggest that ligands that increase acinar cell cAMP levels can sensitize the acinar cell to the effects of CCK-induced zymogen activation.
authors.affiliation: GI Research Laboratory, Veterans Affairs Healthcare Connecticut, 950 Campbell Ave., West Haven, CT 06516, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Lu
authors.forename: T R
authors.initials: TR
authors.lastname: Kolodecik
authors.forename: S
authors.initials: S
authors.lastname: Karne
authors.forename: M
authors.initials: M
authors.lastname: Nyce
authors.forename: F
authors.initials: F
authors.lastname: Gorelick
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002108:Ceruletide / Q000494:pharmacology*; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004792:Enzyme Precursors / Q000502:physiology*; D005765:Gastrointestinal Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D008024:Ligands; D008297:Male; D009479:Neuropeptides / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051381:Rats; D017207:Rats, Sprague-Dawley; D012633:Secretin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: C495403:Adcyap1 protein, rat; D004792:Enzyme Precursors; D005765:Gastrointestinal Agents; D008024:Ligands; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012633:Secretin; D015124:8-Bromo Cyclic Adenosine Monophosphate; D014660:Vasoactive Intestinal Peptide; D002108:Ceruletide; D000242:Cyclic AMP